• The presence of mutations in the BRAF gene in tumor tissues and/or in circulating tumor DNA (ctDNA) at any stage of treatment or follow-up.

• Failure of the treatment (at least one of below needs to apply in order for this requirement to be satisfied):

‣ Progression on the I and/or II line treatment, including at least one risk organ; prior treatment should include a minimum of 6 weeks of weekly Vinblastine with a minimum of 28 days prednisolone or minimum 2 cycles of Cytosine Arabinoside in 4-day cycles and/or Cladribine in 5-day cycles as a 2nd line treatment, minimum 2 cycles, or other second-line treatment or

⁃ Disease reactivation after an initial response to treatment with Vimblastine and prednisolone as the first line and/or no response to second line treatment using one of two drugs: Cytosine Arabinoside in 4-day cycles and/or Cladribine in 5-day cycles, minimum 2 cycles, or other I/ II line treatment or occurrence of involvement of at least one risk organ or

⁃ Third or subsequent reactivation of disease with or without risk organ involvement, or

⁃ Reactivation of disease after Vemurafenib therapy has been completed, or

⁃ The appearance of signs of neurodegenerative disorder (ND) in MRI of the central nervous system (CNS).

• Signing of informed consent for trial participation (including for Vemurafenib treatment) according with current legal regulations.

• Consent to the use of effective contraception throughout the Vemurafenib administration period and a minimum of 1 year after discontinuation in patients at puberty and sexual maturity.

• Participation in HISTIOGEN trial.